Picture loading failed.

Anti-IL1A therapeutic antibody (Pre-made Bermekimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-063-1mg 1mg 3090
GMP-Bios-ab-063-10mg 10mg 21890
GMP-Bios-ab-063-100mg 100mg 148000
GMP-Bios-ab-063-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL1A therapeutic antibody (Pre-made Bermekimab biosimilar,Whole mAb)
INN Name Bermekimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesXBiotech Inc.
Conditions Approvedna
Conditions ActiveColorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer
Conditions DiscontinuedHaematological malignancies
Development Techna